|Other Names||Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3, Cyclin-dependent kinase 4 inhibitor A, CDK4I, Multiple tumor suppressor 1, MTS-1, p16-INK4a, p16-INK4, p16INK4A, CDKN2A, CDKN2, MTS1|
|Format||Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.|
|Cellular Location||Cytoplasm. Nucleus|
|Tissue Location||Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene generates several transcript variants whichdiffer in their first exons. At least three alternatively splicedvariants encoding distinct proteins have been reported, two ofwhich encode structurally related isoforms known to function asinhibitors of CDK4 kinase. The remaining transcript includes analternate first exon located 20 Kb upstream of the remainder of thegene; this transcript contains an alternate open reading frame(ARF) that specifies a protein which is structurally unrelated tothe products of the other variants. This ARF product functions as astabilizer of the tumor suppressor protein p53 as it can interactwith, and sequester, MDM1, a protein responsible for thedegradation of p53. In spite of the structural and functionaldifferences, the CDK inhibitor isoforms and the ARF product encodedby this gene, through the regulatory roles of CDK4 and p53 in cellcycle G1 progression, share a common functionality in cell cycle G1control. This gene is frequently mutated or deleted in a widevariety of tumors, and is known to be an important tumor suppressorgene.
Kovacs, E., et al. Proc. Natl. Acad. Sci. U.S.A. 107(12):5429-5434(2010)Irvine, M., et al. Cell Cycle 9(4):829-839(2010)Zhang, H.J., et al. J. Cell. Biochem. 106(3):464-472(2009)Ivanchuk, S.M., et al. Cell Cycle 7(12):1836-1850(2008)Bandyopadhyay, K., et al. Biochemistry 46(49):14325-14334(2007)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.